Literature DB >> 17331980

COG8 deficiency causes new congenital disorder of glycosylation type IIh.

Christian Kranz1, Bobby G Ng, Liangwu Sun, Vandana Sharma, Erik A Eklund, Yoshiaki Miura, Daniel Ungar, Vladimir Lupashin, R Dennis Winkel, John F Cipollo, Catherine E Costello, Eva Loh, Wanjin Hong, Hudson H Freeze.   

Abstract

We describe a new Type II congenital disorder of glycosylation (CDG-II) caused by mutations in the conserved oligomeric Golgi (COG) complex gene, COG8. The patient has severe psychomotor retardation, seizures, failure to thrive and intolerance to wheat and dairy products. Analysis of serum transferrin and total serum N-glycans showed normal addition of one sialic acid, but severe deficiency in subsequent sialylation of mostly normal N-glycans. Patient fibroblasts were deficient in sialylation of both N- and O-glycans, and also showed slower brefeldin A (BFA)-induced disruption of the Golgi matrix, reminiscent of COG7-deficient cells. Patient fibroblasts completely lacked COG8 protein and had reduced levels and/or mislocalization of several other COG proteins. The patient had two COG8 mutations which severely truncated the protein and destabilized the COG complex. The first, IVS3 + 1G > A, altered the conserved splicing site of intron 3, and the second deleted two nucleotides (1687-1688 del TT) in exon 5, truncating the last 47 amino acids. Lentiviral-mediated complementation with normal COG8 corrected mislocalization of other COG proteins, normalized sialylation and restored normal BFA-induced Golgi disruption. We propose to call this new disorder CDG-IIh or CDG-II/COG8.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331980     DOI: 10.1093/hmg/ddm028

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  60 in total

1.  Delineating diseases by IMS-MS profiling of serum N-linked glycans.

Authors:  Dragan Isailovic; Manolo D Plasencia; Maissa M Gaye; Sarah T Stokes; Ruwan T Kurulugama; Vitara Pungpapong; Min Zhang; Zuzana Kyselova; Radoslav Goldman; Yehia Mechref; Milos V Novotny; David E Clemmer
Journal:  J Proteome Res       Date:  2011-12-30       Impact factor: 4.466

2.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

3.  Identification of the first COG-CDG patient of Indian origin.

Authors:  Bobby G Ng; Vandana Sharma; Liangwu Sun; Eva Loh; Wanjin Hong; Stacey K H Tay; Hudson H Freeze
Journal:  Mol Genet Metab       Date:  2010-11-24       Impact factor: 4.797

Review 4.  Role of the conserved oligomeric Golgi (COG) complex in protein glycosylation.

Authors:  Richard D Smith; Vladimir V Lupashin
Journal:  Carbohydr Res       Date:  2008-02-02       Impact factor: 2.104

5.  Cog2 null mutant CHO cells show defective sphingomyelin synthesis.

Authors:  Waldo Spessott; Andrea Uliana; Hugo J F Maccioni
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

6.  Direct interaction between the COG complex and the SM protein, Sly1, is required for Golgi SNARE pairing.

Authors:  Orly Laufman; Amir Kedan; Wanjin Hong; Sima Lev
Journal:  EMBO J       Date:  2009-06-18       Impact factor: 11.598

Review 7.  Localization of Golgi-resident glycosyltransferases.

Authors:  Linna Tu; David Karl Banfield
Journal:  Cell Mol Life Sci       Date:  2009-09-01       Impact factor: 9.261

8.  Conserved oligomeric Golgi complex specifically regulates the maintenance of Golgi glycosylation machinery.

Authors:  Irina D Pokrovskaya; Rose Willett; Richard D Smith; Willy Morelle; Tetyana Kudlyk; Vladimir V Lupashin
Journal:  Glycobiology       Date:  2011-03-18       Impact factor: 4.313

Review 9.  Understanding human glycosylation disorders: biochemistry leads the charge.

Authors:  Hudson H Freeze
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

Review 10.  Glycosylation Quality Control by the Golgi Structure.

Authors:  Xiaoyan Zhang; Yanzhuang Wang
Journal:  J Mol Biol       Date:  2016-03-05       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.